The metabolic syndrome and schizophrenia

Acta Psychiatrica Scandinavica

Volumn 119, Issue 1, 2009, Pages 4-14

  Meyer, J M ^a,b,c   Stahl, S M ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Atypical antipsychotic; Cardiovascular; Insulin resistance; Metabolic; Triglycerides

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; METFORMIN; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

BIBLIOGRAPHIC DATABASE; DISEASE PREDISPOSITION; FEMALE; HUMAN; INSULIN RESISTANCE; LIFESTYLE; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DIABETIC DIET; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MASS SCREENING; METABOLIC SYNDROME X; PREDIABETIC STATE; RISK FACTORS; SCHIZOPHRENIA;

EID: 57449083235     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2008.01317.x     Document Type: Review

References (94)

1. de Vegt F, Dekker JM, Jager A et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001 285 : 2109 2113.
2. Ford ES, Abbasi F, Reaven GM. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 2005 181 : 143 148.
3. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004 173 : 309 314.
4. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007 298 : 1794 1796.
5. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007 64 : 1123 1131.
6. Bushe C, Holt R. Prevalence of diabetes and glucose intolerance in patients with schizophrenia. Br J Psychiatry 2004 184 : 67 71.
7. McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005 80 : 19 32.
8. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004 53 : 1195 1200.
9. Stahl SM, Mignon L, Meyer JM. What comes first: atypical antipsychotics or the metabolic syndrome? Acta Psychiatr Scand 2008 (in press).
10. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007 298 : 2654 2664.
11. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003 64 : 575 579.
12. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004 49 : 753 760.
13. De Hert MA, van Winkel R, van Eyck D et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006 83 : 87 93.
14. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006 21 : 93 98.
15. Meyer J, Loh C, Leckband SG et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 2006 12 : 5 10.
16. Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007 191 : 23 29.
17. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 2007 7 : 14.
18. Saari KM, Lindeman SM, Viilo KM et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005 66 : 559 563.
19. Suvisaari JM, Saarni SI, Perala J et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007 68 : 1045 1055.
20. Tirupati S, Chua L-E. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry 2007 41 : 606 610.
21. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002 26 : 137 141.
22. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003 160 : 284 289.
23. Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia [erratum appears in Life Sci. 2004 Oct 22; 75(23):2851]. Life Sci 2004 74 : 1999 2008.
24. Zhang Z-J, Yao Z-J, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004 184 : 58 62.
25. Arranz B, Rosel P, Ramirez N et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004 65 : 1335 1342.
26. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TMS. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 2006 51 : 382 386.
27. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007 24 : 481 485.
28. Venkatasubramanian G, Chittiprol S, Neelakantachar N et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007 164 : 1557 1560.
29. van Nimwegen LJM, Storosum JG, Blumer RME et al. Hepatic insulin resistance in antipsychotic naive patients with schizophrenia, a detailed study of glucose metabolism with stable isotopes. J Clin Endocrinol Metab 2008 93 : 572 577.
30. Ader M, Garvey WT, Phillips LS et al. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J Psychiatr Res 2008 42 : 1076 1085.
31. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004 65 : 267 272.
32. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 1223.
33. McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006 163 : 600 610.
34. Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006 163 : 611 622.
35. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005 19 (suppl. 1 1 93.
36. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007 32 : 289 297.
37. Wagenknecht LE, Langefeld CD, Scherzinger AL et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2003 52 : 2490 2496.
38. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004 70 : 1 17.
39. Smith DA. Treatment of the dyslipidemia of insulin resistance. Med Clin North Am 2007 91 : 1185 1210.
40. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003 139 : 802 809.
41. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998 97 : 1029 1036.
42. Eberly LE, Stamler J, Neaton JD, Multiple Risk Factor Intervention Trial Research G. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003 163 : 1077 1083.
43. Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007 298 : 299 308.
44. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007 298 : 309 316.
45. Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004 161 : 1334 1349.
46. De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J. Conference report: Belgian consensus on metabolic problems associated with second-generation antipsychotics. Int J Psychiatry Clin Pract 2005 9 : 130 137.
47. Poulin M-J, Cortese L, Williams R, Wine N, McIntyre RS. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Can J Psychiatry 2005 50 : 555 562.
48. De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006 21 (suppl. 2 S11 S15.
49. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
50. Rosenfalck AM, Hendel H, Rasmussen MH et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab 2002 4 : 19 28.
51. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003 108 : 324 332.
52. Werneke U, Taylor D, Sanders TAB, Wessely S. Behavioural management of antipsychotic-induced weight gain: a review. Acta Psychiatr Scand 2003 108 : 252 259.
53. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005 66 : 205 212.
54. Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry 2006 18 : 23 31.
55. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006 67 : 1253 1260.
56. Kwon JS, Choi J-S, Bahk W-M et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry 2006 67 : 547 553.
57. Casey DE, Carson WH, Saha AR et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology 2003 166 : 391 399.
58. Weiden PJ, Daniel DG, Simpson GM, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003 23 : 1 6.
59. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005 27 : 1930 1941.
60. Weiden PJ, Newcomer JW, Loebel A, Yang R, Lebovitz H. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008 33 : 985 994.
61. Gupta S, Masand PS, Virk S et al. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 2004 70 : 57 62.
62. Ball MP, Hooper ET, Skipwith DAF, Cates ME. Clozapine-induced hyperlipidemia resolved after switch to aripiprazole therapy. Ann Pharmacother 2005 39 : 1570 1572.
63. De Hert M, Hanssens L, van Winkel R et al. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes Care 2006 29 : 2329 2330.
64. Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. J Am Pharm Assoc 2007 47 : 373 378.
65. Ried LD, McConkey JR, Bengtson MA, Garman PM, Hsu C, Rahnavard F. Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia-related disorders. J Am Pharm Assoc 2007 47 : 156 164.
66. Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007 68 : 406 409.
67. Kim SH, Ivanova O, Abbasi FA, Lamendola CA, Reaven GM, Glick ID. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol 2007 27 : 365 368.
68. Montes JM, Rodriguez JL, Balbo E et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry 2007 31 : 383 388.
69. Weiden PJ, Miller AL, Lambert TJ, Buckley PF. The art and science of switching antipsychotic medications, part 2. J Clin Psychiatry 2007 68 : e02.
70. Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry 2007 68 (suppl. 4 34 39.
71. Baptista T, Hernandez L, Prieto LA, Boyero EC, de Mendoza S. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 2001 62 : 653 655.
72. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002 159 : 655 657.
73. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006 163 : 2072 2079.
74. Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res 2006 83 : 95 101.
75. Baptista T, Martinez J, Lacruz A et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006 51 : 192 196.
76. Baptista T, Rangel N, Fernandez V et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007 93 : 99 108.
77. Wu R-R, Zhao J-P, Jin H et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008 299 : 185 193.
78. Tupper T, Gopalakrishnan G. Prevention of diabetes development in those with the metabolic syndrome. Med Clin North Am 2007 91 : 1091 1105.
79. Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am 2007 91 : 1063 1077.
80. Tarcin O, Bajaj M, Akalin S. Insulin resistance, adipocyte biology, and thiazolidinediones: a review. Metab Syndr Relat Disord 2007 5 : 103 115.
81. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007 298 : 1189 1195.
82. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007 370 : 1129 1136.
83. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007 298 : 194 206.
84. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 368 : 1696 1705.
85. Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 2007 7 : 557 568.
86. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, Sitagliptin Study G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007 9 : 194 205.
87. Raz I, Hanefeld M, Xu L et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006 49 : 2564 2571.
88. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 28 : 1556 1568.
89. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007 61 : 171 180.
90. Mu J, Woods J, Zhou Y-P et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006 55 : 1695 1704.
91. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006 67 : 575 583.
92. Lamberti JS, Olson D, Crilly JF et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006 163 : 1273 1276.
93. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 2497.
94. Assmann G, Guerra R, Fox G et al. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. Am J Cardiol 2007 99 : 541 548.